SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is actively debated as its strong correlation to Bitcoin's recent downturn fuels significant selling pressure, while speculation around its potential role in managing "Trump accounts" for children offers a contrasting catalyst for future growth and new inflows.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is drawing intense community attention due to its CEO's comments hinting at a "monumental" acquisition of a publicly traded consumer company, fueling widespread speculation on potential targets and reigniting discussions around its strong cash position and perceived market manipulation.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is trending following its strategic partnership with OpenAI to integrate its extensive IP with Sora, driving market conversation around its AI future. This coincides with its latest earnings report, showcasing strong theme park performance and streaming profitability, supported by a new share buyback program, despite some lingering investor skepticism about the stock's long-term growth.

VenHub Global, Inc. engages in the management of fully autonomous and robotic-operated convenience stores. It is involved in utilizing technologies such as artificial intelligence (AI) and smart inventory management systems for shopping experience of customers. The company was founded by Shahan Ohanessian and Shoushana Ohanessian on January 31, 2023 and is headquartered in Pasadena, CA.

Venhub Global Inc.

Venhub Global Inc. (VHUB) is trending significantly following its recent direct listing on Nasdaq, with community discussions centered on its perceived low float and strong pre-market volume driving speculation for a supply-demand-fueled rally in the automated retail space.

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Atossa Therapeutics Inc

Atossa Therapeutics is trending due to its upcoming 1-for-15 reverse stock split, which is fueling widespread community frustration over perceived mismanagement and fears of further dilution; a recent FDA Orphan Drug Designation for Duchenne Muscular Dystrophy, while new, is met with skepticism amid ongoing concerns about the company's long-term strategy.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as Microsoft and Meta's significantly increased CapEx for AI infrastructure highlights critical demand, fueling community anticipation for imminent, large-scale AI cloud deals for IREN's power-rich data centers, a key factor in its strategic pivot from Bitcoin mining.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical (PBM) is actively discussed following recent approval to use its psilocybin product in a Phase IIb clinical trial for cancer patients, coupled with a CEO letter highlighting clinical progress, a strong cash position, and expansion into longevity research. The community is focused on its extremely low float, institutional interest, and the potential for significant volatility amidst ongoing discussions about its share structure.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is plummeting to new all-time lows, sparking intense investor frustration over perceived management silence and concerns about dilution from a Yorkville agreement, even as some in the community see the extreme sell-off as an undervalued buying opportunity amidst broader fintech and crypto market pressures.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as it stages a significant V-shaped recovery from steep overnight lows, fueling a heated debate between resilient bulls celebrating a 'buy the dip' success and frustrated bears decrying perceived market manipulation.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

ProShares UltraShort Bloomberg Natural Gas ($KOLD) is surging as natural gas futures plummet due to warmer weather forecasts and recovering production, sparking intense trading and profit-taking among investors capitalizing on the inverse ETF's volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

iBio (NASDAQ:IBIO) Stock Price Down 3.6% - Here's Why

iBio (NASDAQ:IBIO) Trading Down 3.6% - What's Next...

<ul class="summary-bullets"><li>iBio intends to use the proceeds from the private placement toward advancing its preclinical cardiometabolic programs.</li><li>This includes the IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs.</li><li>The company also stated that it will use the funds to continue to progress other preclinical assets in the pipeline.</li></ul>Shares of iBio Inc. (IBIO) surged more than 12% in Friday’s pre-market trade after the company announced a private placement of securities worth $26 million.In its announcement, iBio stated that it has entered into a securities purchase agreement with existing healthcare-focused, high-quality institutional investors for private placement financing. It expects the offering to close on or about Jan. 13, 2026, subject to customary closing conditions.iBio stated that it is selling more than 11 million shares of its common stock at a purchase price of $2.35 apiece.<h2 class="st-heading-2">Here’s What iBio Intends To Use Funds For</h2>In its announcement, iBio noted that it intends to use the proceeds from the private placement toward advancing its preclinical cardiometabolic programs. This includes the IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs.Additionally, iBio said it will use the funds to advance other preclinical assets in the pipeline. The balance, if any, would be used toward meeting the company’s working capital requirements, iBio stated.The company added that the $26 million private placement extends its cash runway into 2028. It is also worth nearly 50% of iBio’s current market capitalization, which stood at nearly $53 million on Thursday.<h2 class="st-heading-2">What Does iBio Do?</h2>iBio is a San Diego, California-based company that is working on the development of cardiometabolic and obesity medicines to promote higher quality weight loss and enhance overall metabolic health and function.The company states that current GLP-1 treatments result in muscle loss in addition to fat loss. However, its therapeutic candidates for cardiometabolic diseases and obesity aim to preserve and build muscle mass during weight loss.iBio says it uses its patented artificial intelligence and machine learning platform to accelerate the discovery of novel therapies for obesity and cardiometabolic disorders.<h2 class="st-heading-2">Here’s What Stocktwits Users Think</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/IBIO">iBio</a> trended in the ‘neutral’ territory at the time of writing.One user on the platform stated that the private placement is “bullish” news for the company, and that the “science here intrigues the industry.”<stembedurl>https://stocktwits.com/MiltonMilkyMilkovich/message/641313031</stembedurl><a href="https://stocktwits.com/symbol/IBIO">IBIO stock</a> is up 22% year-to-date, but down 14% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/what-is-fueling-smr-stock-surge-today/cmU2QIKR4dB">What Is Fueling SMR Stock's Surge Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

IBIO Stock Soars 12% Pre-Market After Company Announces $26 Million Private Placement

iBio stated that it is selling more than 11 million shares of its common stock at a purchase price of $2.35 apiece.

Equity

Best Penny Stocks To Consider - December 10th

iBio, iBio, Momentus, Bitfarms, Richtech Robotics, Bit Digital, and Strive are the seven Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced shares...

Top Manufacturing Stocks To Keep An Eye On - December 10th

Taiwan Semiconductor Manufacturing, Applied Materials, Johnson Controls International, Flex, iBio, FREYR Battery, and Fabrinet are the seven Manufacturing stocks to watch today, according to...

Manufacturing Stocks To Research - December 8th

Taiwan Semiconductor Manufacturing, Applied Materials, Flex, Johnson Controls International, and iBio are the five Manufacturing stocks to watch today, according to MarketBeat's stock screener tool...

Best Biotech Stocks To Keep An Eye On - December 8th

WAVE Life Sciences, Vertex Pharmaceuticals, iBio, argenex, and Cidara Therapeutics are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares...

iBio, Inc. (IBIO) Reports Q1 Loss

iBio (IBIO) delivered earnings and revenue surprises of -57.14% and 0.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of iBio, Inc.(IBIO) were in the spotlight on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/04/07/3056559/0/en/iBio-Announces-IBIO-600-Non-Human-Primate-Data-Showing-Extended-Half-Life-and-Muscle-Growth-and-Interim-In-Vivo-Results-for-First-in-Class-Activin-E-Antibody-Advancing-Cardiometabo.html">announced</a> positive data from a study conducted in animals for its lead asset IBIO-600.The company said data from a study on elderly and obese non-human primates shows that the anti-myostatin antibody could provide a weight loss treatment option while preserving and promoting muscle growth.The study consisted of a single administration of two dose levels: 5mg/kg and a high dose of 50mg/kg.Shares of the company were down by over 43% on Monday noon amid a broader market decline.Notably, the study does not prove statistical significance and only involves a single administration of the antibody.However, the study demonstrated an extended half-life for the antibody, potentially enabling a once three to six-month dosing schedule in humans, the company said.CEO Martin Brenner said the company is on track for a regulatory submission for the antibody in the first quarter (Q1) of 2026.iBio in-licensed IBIO-600 from AstralBio, Inc. in January. The company paid AstralBio $750,000 by issuing its common stock as an upfront payment and said AstralBio will also be eligible for development and commercialization milestone payments totaling up to $28 million.On Monday, the company also announced preclinical data for an Activin E antibody and said that the antibody showed positive results in an exploratory study with obese mice, highlighting its potential as a treatment for obesity.On Stocktwits, retail sentiment about iBio remained in the ‘bearish’ territory while message volume rose marginally within ‘low’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:654/152;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_07_at_11_29_58_AM_png_24aaec3e9f.webp" alt="IBIO's Sentiment Meter and Message Volume as of 11:30 a.m. ET on April 7, 2025 | Source: Stocktwits" width="654" height="152"><figcaption>IBIO's Sentiment Meter and Message Volume as of 11:30 a.m. ET on April 7, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed surprise at the stock’s downward trajectory.<stembedurl>https://stocktwits.com/Skypier2/message/610731384</stembedurl>Another opined that the company needs to protect itself against any potential hostile takeovers.<stembedurl>https://stocktwits.com/dcpanda/message/610733604</stembedurl><a href="https://stocktwits.com/symbol/IBIO">iBio shares</a> are down by over 24% this year and by over 19% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/federal-reserve-board-of-governors-will-meet-today/chf1DjqRb7o">Federal Reserve Board Of Governors Will Meet Today — Traders Factor In 4 Rate Cuts This Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

iBio Stock Plummets Despite Positive Data On Weight-Loss Treatment Antibody: Retail Stays Bearish

However, the company said that the study does not prove statistical significance and only involves a single administration of the antibody. 

Biotechs have underperformed the broader market this year, and these stock are at crossroads as they await the new administration under Donald Trump to take over shortly after the new year.The SPDR S&amp;P Biotech ETF ($XBI) has gained 9.2% for the year-to-date period compared to the 25%+ gain for the S&amp;P 500 Index. The iShares Biotechnology ETF ($IBB), which has a relatively higher proportion of mid- and large-cap stocks, has also added under 10% so far this year.The underperformance takes away the sheen of the industry’s defensive credentials.&nbsp;R&amp;D momentum slowed during the year, as is evident from the new molecular entity approvals, which number 38 so far this year compared to 47 for the same period last year.&nbsp;&nbsp;Most biotech companies operate deep in the red for a very long time until they could begin commercializing products. They rely on debt financing which came to be expensive in an elevated interest rate environment.&nbsp;With a change of guard on the political arena following Trump's win, the outlook for the industry is yet unclear.Morgan Stanley Head of Policy Monica Guerra&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.morganstanley.com/articles/trump-re-election-implications-for-markets">said&nbsp;</a>in a recent note that deregulation is likely to be a major theme expected during the second term. “Less stringent requirements in pharmaceuticals and biotechnology, meanwhile, could help those industries by prompting accelerated drug approvals,” she said.BMO Capital Markets analyst Evan Seigerman said the election results are “modestly positive” for the biopharma sector,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fiercepharma.com/pharma/trump-white-house-again-whats-ahead-pharma">according</a> to FiercePharma. The analyst sees potential deprioritization of the Internal Revenue Service, likely less Federal Trade Commission interference, and lower corporate taxes.Jefferies analysts does not expect the proposed drug pricing reforms to pass as the Republican legislators are divided over the proposals.Amid the ongoing discussions about the implications of Trump’s presidency, here’s a few biopharma stocks that are on retail’s radar (based on the number of followers on the Stocktwits platform):Moderna, Inc. ($ MRNA): 107,109 watchersNovavax, Inc. ($NVAX): 101,846Pfizer, Inc. ($PFE): 99,425 watchersiBio, Inc. ($IBIO): 93,617 watchersInovia Pharma, Inc. ($INO): 93,414 watchersJaguar Health ($JAGX): 81,859 watchersGilead Sciences, Inc. ($GILD): 77,094 watchersVaxart, Inc. ($VXRT): 75,807 watchersTonix Pharmaceutical Holding Corp. ($TNXP): 72,666 watchersSorrento Therapeutics, Inc. ($SRNE): 68,474 watchersRead Next:&nbsp; <a href="https://stocktwits.com/news-articles/markets/equity/block-ceo-jack-dorsey-weighs-in-on-election-impact/cJ4EMJ3Raj">Block CEO Jack Dorsey Keeps Fingers Crossed Over Regulatory Environment As Trump Makes A Comeback</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

GOP lawmakers are divided over drug pricing reforms.

Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

Current Price	$2.16
Prev Close	$2.10
Open	$2.09
Dividend Yield	0.00%
50-Day Moving Average	$1.88
Beta	1.28
Avg. Volume	12.39M
PE Ratio	-1.51

52-Week High	$6.89
52-Week Low	$0.5562
Market Capitalization	$47.22M
EPS (Annual)	-$1.75
Price to Book	0.76
Revenue Per Employee	$20,000.00
Enterprise Value/EBITDA	N/A

IBIO
iBio Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IBIO News

IBIOiBio Inc